A citation-based method for searching scientific literature

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Fang Wang, Jeremy Travins, Byron DeLaBarre, Virginie Penard-Lacronique, Stefanie Schalm, Erica Hansen, Kimberly Straley, Andrew Kernytsky, Wei Liu, Camelia Gliser, Hua Yang, Stefan Gross, Erin Artin, Veronique Saada, Elena Mylonas, Cyril Quivoron, Janeta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, Shunqi Yan, Stuart Murray, Wentao Wei, Yi Gao, Lenny Dang, Marion Dorsch, Sam Agresta, David P Schenkein, Scott A Biller, Shinsan M Su, Stephane de Botton, Katharine E Yen. Science 2013
Times Cited: 573



Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Lenny Dang, David W White, Stefan Gross, Bryson D Bennett, Mark A Bittinger, Edward M Driggers, Valeria R Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C Keenan, Kevin M Marks, Robert M Prins, Patrick S Ward, Katharine E Yen, Linda M Liau, Joshua D Rabinowitz, Lewis C Cantley, Craig B Thompson, Matthew G Vander Heiden, Shinsan M Su. Nature 2009
Times Cited: 2336




List of shared articles



Times cited

Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review.
Sajad Fakhri, Seyed Zachariah Moradi, Mohammad Hosein Farzaei, Anupam Bishayee. Semin Cancer Biol 2022
24

Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.
Ingo K Mellinghoff, Susan M Chang, Kurt A Jaeckle, Martin van den Bent. Hematol Oncol Clin North Am 2022
0

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma.
Gabriel Alzial, Ophelie Renoult, François Paris, Catherine Gratas, Anne Clavreul, Claire Pecqueur. Oncogene 2022
1

Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
Meng-Ju Wu, Lei Shi, Juan Dubrot, Joshua Merritt, Vindhya Vijay, Ting-Yu Wei, Emily Kessler, Kira E Olander, Ramzi Adil, Amaya Pankaj,[...]. Cancer Discov 2022
4

Post-translational modifications on mitochondrial metabolic enzymes in cancer.
Yunhua Peng, Huadong Liu, Jiankang Liu, Jiangang Long. Free Radic Biol Med 2022
1

Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
Xuechen Zhou, Mengzhu Zheng, Na Zhao, Yixin Hu, Kaiyin Yang, Junfeng Huo, Guangyuan Liu, Jiangeng Huang, Lixia Chen, Yirong Zhou,[...]. Bioorg Chem 2022
0

IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
Remco J Molenaar, Johanna W Wilmink. J Histochem Cytochem 2022
1

Biology of IDH mutant cholangiocarcinoma.
Meng-Ju Wu, Lei Shi, Joshua Merritt, Andrew X Zhu, Nabeel Bardeesy. Hepatology 2022
0

IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis.
Zuzana Sporikova, Rastislav Slavkovsky, Lucie Tuckova, Ondrej Kalita, Magdalena Megova Houdova, Jiri Ehrmann, Marian Hajduch, Lumir Hrabalek, Miroslav Vaverka. Appl Immunohistochem Mol Morphol 2022
0

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.
Adriane Halik, Christopher Maximilian Arends, Lars Bullinger, Frederik Damm, Mareike Frick. Cancers (Basel) 2022
0

Targeting mutations in cancer.
Michael R Waarts, Aaron J Stonestrom, Young C Park, Ross L Levine. J Clin Invest 2022
0

Targeting allosteric regulation of cancer metabolism.
Daniel M Kremer, Costas A Lyssiotis. Nat Chem Biol 2022
0

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma.
Su Min Cho, Abdullah Esmail, Ali Raza, Sunil Dacha, Maen Abdelrahim. Cancers (Basel) 2022
0

Metabolic reprogramming and epigenetic modifications on the path to cancer.
Linchong Sun, Huafeng Zhang, Ping Gao. Protein Cell 2022
12

IDH mutation and cancer stem cell.
Yang Zhang, Yang Liu, Fengchao Lang, Chunzhang Yang. Essays Biochem 2022
0

Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
Xuewei Bai, Hongyu Zhang, Yamei Zhou, Katsuya Nagaoka, Jialin Meng, Chengcheng Ji, Dan Liu, Xianghui Dong, Kevin Cao, Joud Mulla,[...]. Hepatology 2021
6

Identification of new IDH2R140Q inhibitors by discriminatory analysis-based molecular docking and biological evaluation.
Xiaoyun Chen, Xianmin Wu, Jian Gao, Huazhou Ying, Xiaowu Dong, Jinxin Che, Zhijian Shen. Arch Pharm (Weinheim) 2021
1

R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis.
Ying Qing, Lei Dong, Lei Gao, Chenying Li, Yangchan Li, Li Han, Emily Prince, Brandon Tan, Xiaolan Deng, Collin Wetzel,[...]. Mol Cell 2021
56

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Xuemin Jiang, Russ Wada, Bill Poland, Huub Jan Kleijn, Bin Fan, Guowen Liu, Hua Liu, Stephanie Kapsalis, Hua Yang, Kha Le. Clin Transl Sci 2021
2

Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Bi-Feng Yuan. Adv Exp Med Biol 2021
2

Exploring the Allosteric Territory of Protein Function.
Wei-Ven Tee, Zhen Wah Tan, Keene Lee, Enrico Guarnera, Igor N Berezovsky. J Phys Chem B 2021
9

Advances in epigenetic therapeutics with focus on solid tumors.
Ning Jin, Tiffany L George, Gregory A Otterson, Claire Verschraegen, Haitao Wen, David Carbone, James Herman, Erin M Bertino, Kai He. Clin Epigenetics 2021
13

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Feng Wang, Kiyomi Morita, Courtney D DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, Keyur P Patel, Kyle J MacBeth, Bin Wu, Guowen Liu,[...]. Nat Commun 2021
17

Metabolomics in cancer research and emerging applications in clinical oncology.
Daniel R Schmidt, Rutulkumar Patel, David G Kirsch, Caroline A Lewis, Matthew G Vander Heiden, Jason W Locasale. CA Cancer J Clin 2021
46

Quantitation of ivosidenib in human plasma via LC-MS/MS and its application in clinical trials.
Feng Yin, Shaoxia Yu, Rohini Narayanaswamy, Heidi Mangus, Erin McCourt, Guowen Liu. Bioanalysis 2021
0

Mitochondrial DNA variation and cancer.
Piotr K Kopinski, Larry N Singh, Shiping Zhang, Marie T Lott, Douglas C Wallace. Nat Rev Cancer 2021
15

A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Mohammed Khurshed, Remco J Molenaar, Myra E van Linde, Ron A Mathôt, Eduard A Struys, Tom van Wezel, Cornelis J F van Noorden, Heinz-Josef Klümpen, Judith V M G Bovée, Johanna W Wilmink. Cancers (Basel) 2021
4

From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy.
Emanuela Di Gregorio, Gianmaria Miolo, Asia Saorin, Agostino Steffan, Giuseppe Corona. Int J Mol Sci 2021
3

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Ghayas C Issa, Courtney D DiNardo. Blood Cancer J 2021
16

Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers.
Juan C García-Cañaveras, Agustín Lahoz. Cancers (Basel) 2021
5

Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Dong Chen, Siyuan Xia, Rukang Zhang, Yuancheng Li, Christopher A Famulare, Hao Fan, Rong Wu, Mei Wang, Allen C Zhu, Shannon E Elf,[...]. Mol Cell 2021
2

A D-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR.
Dan Xiao, Wen Zhang, Xiaoting Guo, Yidong Liu, Chunxia Hu, Shiting Guo, Zhaoqi Kang, Xianzhi Xu, Cuiqing Ma, Chao Gao,[...]. Nat Commun 2021
2

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, Amir T Fathi, Olga Frankfurt, Andre C Schuh, Hartmut Döhner, Giovanni Martinelli, Prapti A Patel, Emmanuel Raffoux,[...]. J Clin Oncol 2021
42

Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview.
Wenwei Yang, Yongkun Sun. Onco Targets Ther 2021
5

Targeting Cancer Metabolism and Current Anti-Cancer Drugs.
Witchuda Sukjoi, Jarunya Ngamkham, Paul V Attwood, Sarawut Jitrapakdee. Adv Exp Med Biol 2021
5

The Mitochondrion as an Emerging Therapeutic Target in Cancer.
Katherine G Roth, Isa Mambetsariev, Prakash Kulkarni, Ravi Salgia. Trends Mol Med 2020
58

Oncometabolites in renal cancer.
Cissy Yong, Grant D Stewart, Christian Frezza. Nat Rev Nephrol 2020
48

Targeting Cell Metabolism as Cancer Therapy.
Natalie Y L Ngoi, Jie Qing Eu, Jayshree Hirpara, Lingzhi Wang, Joline S J Lim, Soo-Chin Lee, Yaw-Chyn Lim, Shazib Pervaiz, Boon Cher Goh, Andrea L A Wong. Antioxid Redox Signal 2020
17

2-Hydroxyglutarate in Cancer Cells.
Petr Ježek. Antioxid Redox Signal 2020
29

Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis.
Xiaotian Zhang, Xinyu Wang, Xue Qing David Wang, Jianzhong Su, Nagireddy Putluri, Ting Zhou, Ying Qu, Mira Jeong, Anna Guzman, Carina Rosas,[...]. Blood 2020
17

Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism.
Di Yu, Yang Liu, Yiqiang Zhou, Victor Ruiz-Rodado, Mioara Larion, Guowang Xu, Chunzhang Yang. Proc Natl Acad Sci U S A 2020
43

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Justin S Becker, Amir T Fathi. Curr Cancer Drug Targets 2020
6


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy